NCT01553656 - Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2015

Study Completion Date

July 31, 2015

Conditions

Solid TumorsCancerNSCLC

Interventions

DRUG

cabozantinib capsules

cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression

DRUG

cabozantinib tablets

cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression

Trial Locations (2)

The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Ariake

National Cancer Center Hospital, Chuo-ku